Hyperpolarized 13C-pyruvate Metabolic MRI With Infiltrating Gliomas
Eligible age
18–80 yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to examine the safety and feasibility of performing hyperpolarized metabolic MRI in the diagnosis of brain tumor. This study will also assess the accuracy of hyperpolarized metabolic MRI to diagnose intermediate to patients with infiltrating gliomas and examine the added utility of metabolic MRI over standard MRI imaging The FDA is allowing the use of hyperpolarized \[1-13C\] pyruvate (HP 13C-pyruvate) in this study. Up to 5 patients may take part in this study at the University of Maryland, Baltimore (UMB).
Sponsor: University of Maryland, Baltimore
You may qualify if…
- ✓ • Patients with a new brain lesion interpreted as suspected infiltrating gliomas including but not limited to (diffuse astrocytoma WHO grade 2; oligodendroglioma WHO grade 2 and 3; anaplastic astrocytoma WHO grade 3; astrocytoma WHO grade 4), OR, patients with prior history of infiltrating glioma scheduled for surgery for tumor biopsy or resection.
- ✓ Ages 18-80, including male and female
- ✓ Suitable to undergo contrast-enhanced MRI
- ✓ Negative serum pregnancy test
You may not qualify if…
- ✕ Inability to undergo MRI scan
- ✕ Inability to receive IV contrast secondary to severe reaction or renal insufficiency.
Where it's recruiting
Baltimore
Source: ClinicalTrials.gov · NCT04772456 · last updated 2025-09-22